Sign In  |  Register  |  About Daly City  |  Contact Us

Daly City, CA
September 01, 2020 1:20pm
7-Day Forecast | Traffic

  • Search Hotels in Daly City

  • CHECK-IN:
  • CHECK-OUT:
  • ROOMS:
Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Gilead Sciences (NQ: GILD )

89.76 +1.13 (+1.27%)
Streaming Delayed Price Updated: 4:00 PM EST, Nov 21, 2024 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Gilead Sciences

< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
26 Analysts Assess Gilead Sciences: What You Need To Know
Via Benzinga
Gilead Unveils Long-Term Data From Seladelpar In Patients With Rare Liver Disease
Gilead shares data from its Phase 3 ASSURE study, showing 81% of PBC patients treated with Livdelzi achieved a composite response with continued safety. 
Via Benzinga
Gilead’s Livdelzi (Seladelpar) Demonstrated a Sustained Efficacy and Long-Term Safety Profile in Management of Primary Biliary Cholangitis
From Gilead Sciences, Inc.
Via Business Wire
Trump's Victory Spurs $50B Corporate Bond Surge As Tax Cut Optimism Drives Borrowing Costs To 25-Year Low
The surge in corporate borrowing is driven by a rally in credit and equity markets, which has pushed borrowing costs to historic lows. 
Via Benzinga
Topics Government
Exposures Political
3 Healthcare Stocks For Long-Term Growth And Dividends
Healthcare stocks will profit from the U.S. aging population and pay rising dividends over time. 
Via Talk Markets
Here's How Much $1000 Invested In Gilead Sciences 20 Years Ago Would Be Worth Today
Via Benzinga
Gilead Sciences's Earnings: A Preview
Via Benzinga
AbTherx and Gilead Expand Collaboration on Innovative Antibody Discovery Technologies
Via ACCESSWIRE
Gilead Prices $3.5 Billion of Senior Unsecured Notes
From Gilead Sciences, Inc.
Via Business Wire
Gilead Presents Full PURPOSE 2 Data Results for Twice-Yearly Lenacapavir for HIV Prevention at HIV Glasgow
From Gilead Sciences, Inc.
Via Business Wire
Scientific Leadership Spotlighted as Gilead Presents Research Data Across Its Broad and Innovative HIV Treatment Portfolio and Pipeline
From Gilead Sciences, Inc.
Via Business Wire
3 Spectacular High-Yield Dividend Stocks to Buy in November
High yields aren't a warning indicator with these three stocks. 
Via The Motley Fool
Gilead Sciences to Present at Upcoming Investor Engagements
From Gilead Sciences, Inc.
Via Business Wire
Bristol-Myers Squibb Leads Biopharma Recovery With Almost 25% Growth In Market Cap, But Novo Nordisk And Lilly Suffer Market Setbacks
The global biopharmaceutical market saw a 2% increase in market capitalization in Q3 2024, led by growth from Bristol-Myers Squibb, Gilead Sciences, and Sanofi, despite challenges for Novo Nordisk and... 
Via Benzinga
Stock Market Surges To Highs On Trump Election; Fed Cuts Rates, Palantir Soars: Weekly Review
A Fed rate cut and a slew of big earnings reports filled out a busy week. 
Via Investor's Business Daily
Topics Economy Government
Exposures Interest Rates Political
Smaller Cap Biotechs Are In Season: How Are We Doing?
SMID biotech stocks still see a lot of speculative interest except for a brief sell-off on August 5 when the XBI touched $91.The XBI is near its 2024 high in the $103 range. 
Via Talk Markets
HIV Drugmaker Gilead Reports Strongest Quarterly Performance Of 2024, Analysts Boost Price Target On Raised Outlook
Gilead stock surges after Q3 earnings beat estimates and raised FY 2024 guidance, with strong HIV drug sales and analyst upgrades boosting investor confidence. 
Via Benzinga
Topics Earnings
Exposures Financial
Nasdaq 100 Extends Record Levels Ahead Of Fed Meeting, Tesla Hits 26-Month Highs, Small Caps Stall: What's Driving Markets Thursday?
After Wednesday’s “everything rally” spurred by the election results, investors took a less euphoric approach on Thursday ahead of the Federal Open Market Committee (FOMC) meeting. The Fed is widely... 
Via Benzinga
Topics Economy
Exposures Interest Rates
Gilead’s Stock Surge: What’s Fueling the Momentum?
Gilead Sciences' financial performance, innovative therapies, and strategic investments position the company for continued growth. 
Via MarketBeat
Late-Breaking Clinical Data and Real-World Evidence Presented at HIV Glasgow as Gilead Extends Leadership Efforts Toward Ending the Epidemic
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences (GILD) Q3 2024 Earnings Call Transcript
GILD earnings call for the period ending September 30, 2024. 
Via The Motley Fool
Topics Earnings
Exposures Financial
Gilead Sciences Announces Third Quarter 2024 Financial Results
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences Easily Beats Third-Quarter Views Driven By Solid Biktarvy Sales
The company also raised its earnings and sales guidance for the year. 
Via Investor's Business Daily
Kite to Highlight Industry-Leading CAR T-Cell Therapy Portfolio at ASH 2024, Including Positive Survival Outcomes in Both Clinical Trials and the Real-World
From Gilead Sciences, Inc.
Via Business Wire
Volatility Hits Large Cap Biopharma: Active Rebalancing May Be Required
A bit of earnings and election jitters roiled the market last week reordering the leaderboard in biopharma stocks. 
Via Talk Markets
Lyell Immunopharma Downgraded, Analyst Flags Concerns Over Acquisition Strategy
Lyell Immunopharma acquires ImmPACT Bio, ends TIL programs, and refocuses on CAR T-cell research. Analyst downgrades reflect concerns over pipeline complexities. 
Via Benzinga
3 Absurdly Cheap Stocks That Pay High Dividends
These stocks are trading at less than 15 times their expected future profits. 
Via The Motley Fool
Healthcare Sector Update: Choppy Days Are Here Again As Yields Rise
There has been a shift in healthcare stock performance by sub-sector which should be confirmed as we move through the Q3 earnings cycle. 
Via Talk Markets
Gilead to Present Latest Research Across Key Liver Disease Indication at the American Association for the Study of Liver Disease (AASLD) Meeting 2024
From Gilead Sciences, Inc.
Via Business Wire
Gilead Sciences/Merck's Investigational Once-Weekly HIV Combo Therapy Shows Sustained Virus Suppression To 48 Weeks
Gilead Sciences and Merck presented Phase 2 results showing 94.2% viral suppression in HIV patients treated with islatravir and lenacapavir. Both weekly and daily treatments achieved comparable success... 
Via Benzinga
< Previous 1 2 3 4 5 6 7 8 9
...
52 53 Next >
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.
 
 
About Us | Contact Us | Privacy Policy | User Agreement | Advertise With Us | Site Map
Copyright © 2010-2020 DalyCity.com & California Media Partners, LLC. All rights reserved.